MedTrace Logo

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

NCT02658448 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-02-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.

Conditions

  • Stress Urinary Incontinence

Interventions

DRUG

GTx-024

GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg

Sponsors & Collaborators

  • GTx

    lead INDUSTRY

Principal Investigators

  • Kenneth M. Peters, MD · William Beaumont Hospitals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658448 on ClinicalTrials.gov